The UK Dementia Research Institute (UK DRI) hosts a virtual roundtable to discuss the promising Phase III trial data of lecanemab for the treatment of Alzheimer’s disease, following presentation of results from Eisai/Biogen at CTAD (Clinical Trials on Alzheimer' Disease conference - Nov 29 2022).
Watch the recording of the webinar on the UK DRI Youtube channel below
The roundtable was intended for an audience of discovery scientists, clinicians, industry and experts in dementia research and drug development field. An expert panel of clinicians and basic researchers dig into the data, providing their perspective on what the results mean for amyloid therapies, drug discovery, trial design, the next steps and more.
Please note: - The webinar was recorded on Tuesday 13 December 2022 - All contributions from all attendees, including panelists, represent the personal opinion of the contributor and expressly do not represent any company or other organisation regardless of any actual or perceived affiliation, employment, branding or logos. -
To find out more about UK DRI, visit our website at www.ukdri.ac.uk, and sign up to our monthly newsletter - https://bit.ly/3V1lIDh